Tag Archives: Valeant Pharmaceuticals

In search of alignment

Good governance used to be about fixing companies and boards. Then came the rise of the shareholder. Now the ideal lies more in bringing the two sides together in a quest for long-term value. Part 1 of our Special Report on Governance
By Paul Brent
May 17th, 2017

As companies work through the last stages of the 2017 proxy season, it’s tempting to ask what’s changed or improved? A small number of proxy fights are generating headlines and attention as activists take aim at perceived underperformance, while other … Continue reading

Posted in Special Reports, Top Stories | Tagged , , , , , , , , , , , , , ,

How to build a pharma giant [and win friends and incite critics]

Valeant Pharmaceuticals has been the biggest story on Canadian markets the past two years. But with a $50-billion takeover in the balance, CEO Michael Pearson’s controversial high-debt, low-R&D model faces its stiffest test yet
By Robert Thompson
August 24th, 2014

Michael Pearson is a divisive figure. To some, he’s shaking up an industry—big pharma—that needed to be rocked to its core, that had become bloated and fat, reliant on spending billions on research and development that often failed to fulfill … Continue reading

Posted in Features, Top Stories | Tagged , , , , , , , , , , ,